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ABSTRACT 
 
 
OBJECTIVES: Extra-articular manifestations (EAMs) are important systemic features of axial spondyloarthritis (axSpA) which may 
influence the choice of TNF-inhibitor (TNFi). We examined the cumulative incidence and predictors of EAMs and the influence of 
these on first TNFi choice in a “real-world” cohort of axSpA patients.  
 
METHODS: Clinical and patient-reported outcomes of 2420 patients with axSpA from 83 centres were collected by British Society for 
Rheumatology Register (BSRBR-AS). Lifestyle factors for EAMs (acute anterior uveitis (AAU), inflammatory bowel diseases (IBD), 
psoriasis) were compared to those without EAMs. Also, the association between pre-treatment EAMs and choice of 1st TNFi 
(adalimumab, etanercept, certolizumab) were analysed. 
 
RESULTS: AAU was directly associated with HLA-B27 (IRR=1.95, 95%CI:1.40- 2.73) and inversely associated with ever-smoking 
(IRR=0.71, 95%CI:0.55-0.92). For both psoriasis and IBD, there was an inverse relationship with HLA-B27 ((IRR=0.54, 95%CI:0.36-
0.79), (IRR=0.63, 95%CI:0.43- 0.91), respectively)). A diagnosis of either AAU (OR=3.79, 95%CI:2.11-6.80) or IBD (OR=5.50, 
95%CI:2.09-14.46) was associated with preference for adalimumab versus others. In contrast, a diagnosis of either AAU (OR=0.14, 
95%CI:0.06-0.33) or IBD (OR=0.17, 95%CI:0.05-0.57) was associated with less preference for etanercept over other TNFi.  
 
CONCLUSION: The higher occurrence of AAU and lower occurrence of psoriasis and IBD in HLA-B27 positive axSpA patients are 
consistent with current pathophysiology. Patients with previous AAU and IBD are more likely to be prescribed adalimumab and less 
likely to receive etanercept, consistent with the superior efficacy of monoclonal TNFi for these indications. Future work will determine 
whether EAMs influence TNFi survival, or effectiveness, and whether this varies between agents. 
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Key Messages 
 
 
What is already known about this subject? 
• Extra-articular manifestations (EAMs) are common and important features of axial spondyloarthritis (axSpA). 
• The efficacy of TNF-inhibitors (TNFi) for EAMs is variable due to their different modes of action. 
 
What does this study add? 
• This study demonstrates that 1 in 3 axSpA patients have at least one EAM, however 84% have a single EAM, suggesting that 
there are unrelated pathogenic mechanisms. 
• Acute anterior uveitis is significantly associated with HLB27, however patients with psoriasis and inflammatory bowel disease 
have lower rates of HLA-B27 positivity than the overall cohort. 
• The presence of EAMs does not increase the likelihood of patients being started on a TNFi, however EAMs do influence TNFi 
choice. 
 
How might this impact on clinical practice or future development? 
• This study raises awareness of potential impact of EAMs on prescribing patterns in axSpA. Longitudinal analysis will 
determine whether EAMs influence TNFi survival and whether or not individual TNFi protect patients from incident or flares of 
existing EAMs.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
INTRODUCTION 
Extra-articular manifestations (EAMs) are common and important systemic features of axial spondyloarthritis (axSpA), the 
commonest being acute anterior uveitis (AAU), inflammatory bowel disease (IBD) and psoriasis. It has previously been estimated 
that the pooled prevalence of AAU, psoriasis and IBD in axSpA are 16-23%, 10-11% and 4-6%, respectively (1). The prevalence of 
EAMs is broadly similar in ankylosing spondylitis (AS; also called radiographic axSpA) and non-radiographic axSpA (nr-axSpA), 
except for AAU prevalence which is higher in AS than nr-axSpA (1).  EAMs contribute to the disease burden and add a layer of 
complexity to the management of axSpA (2, 3).  
National and international recommendations for the management of axSpA consistently highlight the importance of considering 
EAMs when choosing the appropriate tumour necrosis factor inhibitor (TNFi) due to their different modes of action and efficacy in the 
context of individual EAMs (2, 4, 5). In the United Kingdom (UK), Europe and North America, five originator TNFi are currently 
licensed to treat axSpA; adalimumab, certolizumab pegol, etanercept, golimumab and infliximab (AS only). A number of TNFi are 
also licensed to treat psoriasis (all except golimumab) and IBD (ulcerative colitis – adalimumab, infliximab and golimumab; Crohn’s 
disease – adalimumab and infliximab (certolizumab in USA and Switzerland only)). However, no TNFi are currently licensed to treat 
AAU in adults, although adalimumab is licensed to treat non-infectious intermediate, posterior, and panuveitis (6). In post-hoc 
analysis of randomised controlled trials for axSpA and other conditions, as well as in a number of observational studies, it has been 
shown that monoclonal TNFi are efficacious in AAU, with monoclonal antibody TNFi showing superior efficacy over etanercept (7-9).  
EAMs therefore have important implications for the use of TNFi, particularly the soluble fusion protein etanercept, in the management 
of axSpA. However, it is not feasible or ethical to randomize patients with axSpA and specific EAMs to specific treatments in 
conventional randomized controlled trial settings, so data from real-world cohorts is required. Specifically, physicians’ beliefs and 
knowledge about the efficacy and safety of specific TNFi for AAU, IBD and psoriasis are likely to influence their choice of TNFi in 
patients with axSpA. The purpose of this study is to examine the cumulative incidence and predictors for developing EAMs and their 
influence on physicians’ prescribing patterns for the first TNFi in a “real life” cohort of axSpA patients recruited in the UK.  
 
 
 
 
 
 
 
 
 METHODS 
Participants Data 
The British Society for Rheumatology Biologics Register for Ankylosing Spondylitis (BSRBR-AS) is a UK-wide prospective 
observational cohort study of patients with axSpA recruited from 83 centres and fulfilling the Assessment of SpondyloArthritis 
International Society (ASAS) classification criteria (10). The BSRBR-AS study protocol has been published previously (11). Baseline 
data were obtained between December 2012 and June 2017 using a combination of a targeted medical history, participant self-
completed questionnaires and the participants’ medical records. The presence or absence of EAMs (ever diagnosis), defined as 
physician-verified diagnosis of AAU, psoriasis, and IBD, were specifically recorded prior to commencing biologic therapy.  
Demographic data included age, disease duration (time between symptom onset to BSRBRAS baseline visit), body mass index 
(BMI), cigarette smoking status (ever versus never used for this analysis), alcohol consumption, educational status. HLA-B27 status 
were determined from either medical records or analysis of patents’ saliva samples. 
In the original dataset there were only a small proportion of missing data (<5%) in variables of interests, therefore, we haven’t applied  
any imputation methods to our dataset.  
Ethical approval was obtained from the National Research Ethics Service Committee North East—County Durham and Tees Valley 
(reference 11/NE/0374) and signed informed consent was obtained from all participants. 
Statistical Analysis 
Descriptive statistics were used to compare participant characteristics according to presence or absence (ever diagnosis) of AAU, 
psoriasis and IBD (either Crohn’s disease or ulcerative colitis), with central tendencies in groups presented as median and interquartile 
range (IQR), unless otherwise stated. Where necessary, the difference between independent groups was examined using the Mann 
Whitney U test. Poisson log-linear models were used to examine the associations between each EAM (AAU, psoriasis, IBD) and 
demographic, lifestyle and HLA-B27 status. In unadjusted models, estimates of incidence rate ratio (IRR) and relevant 95% confidence 
interval (95%CI) were calculated with one EAM as response and one factor as predictor. In adjusted models, all factors (categorical) 
and covariate (continuous) variables showing significant association (p<0.05) with the response in univariable analysis were entered 
in the model. In final models, when AAU was the response, HLA-B27 (reference: negative), university degree (reference: no) and ever-
smoking (reference: never) were factors, and age (years) and axSpA disease duration (years) were covariates. In the model for 
psoriasis, HLA-B27 (reference: negative), university degree (reference: no) and ever-smoking (reference: never) were factors, and age 
(years) and BMI were covariates. In the model for IBD as response, only HLA-B27 (reference: negative) was entered as factor, and 
age (years) and axSpA disease duration (years) as covariates. For each EAM, the final models’ type was Poisson loglinear, the 
maximum iterations were 100, and maximum step-halving was 5. The convergence criteria defined as a change in parameter estimate 
of 1e-006 or more.  
To examine the associations between EAMs and the choice of first TNFi, logistic regression models were used. In univariable analyses, 
separate models were constructed with etanercept versus monoclonal TNFis as dependent variable, and pre-treatment diagnosis of 
AAU, psoriasis and IBD (as Crohn’s disease only, ulcerative colitis only and combined). Other demographic and lifestyle factors 
included in the models were age, gender, axSpA disease duration, BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) score, 
BASFI (Bath Ankylosing Spondylitis Functional Index) score, HLA-B27 status, smoking status, education and BMI. Factors with 
significant associations (p<0.05) in univariable models were entered into multivariable model, again with choice of TNFi (etanercept vs 
monoclonal TNFis) as dependent variable. Pre-treatment diagnosis of AAU, IBD, education status, BASDAI and BASFI were included 
in the final model. The enter method was chosen for the final multivariable analyses to keep all variable in the model. Magnitude of 
associations were presented as odds ratios (ORs) and 95%CI. 
 
 
 
RESULTS 
Baseline data for 2419 participants were available for the current analysis. Approximately a third of the cohort (927; 32%) had one or 
more EAM of interest present prior to receiving biologic therapy; of these 780 (84.1%) had only one EAM, 142 (15.3%) had two 
EAMs and 5 (0.5%) participants had all three EAMs.  The frequency of AAU, psoriasis and IBD at the baseline visit were 23.5% 
(568), 10.9 % (264) and 10.2% (247), respectively.  The baseline demographic, lifestyle factors and HLA-B27 status of the whole 
cohort and those with EAMs are shown in Table 1. 
Associations with AAU 
AAU was the commonest EAM reported in 568 (23.5%) of participants (Table 1). In the univariable analysis, significant positive 
associations in the AAU cohort included; older age (IRR 1.01, 95%CI: 1.01 – 1.021 per year), longer disease duration (IRR 1.02, 
95%CI: 1.01 – 1.02), HLA-B27 (IRR 1.92, 95%CI:1.42 – 2.61) and university education (1.30, 95%CI: 1.08 – 1.57). Conversely, the 
proportion of patients who ever-smoked was significantly lower in the AAU group (IRR 0.77, 95%CI: 0.64 - 0.92). Additional analysis 
revealed a confounding between education and ever-smoking, indicating that the higher occurrence of AAU in those with university 
education was due to lower proportion of ever smoking in that group (ever smoking was 20.9% in those with university degree 
compared to 79.1% in those without a university degree; p<0.001). There were no association between AAU and gender, BMI or 
alcohol consumption.   
In the multivariable analysis (Table 2), HLA-B27 was associated with an increase in the risk of AAU (IRR:1.95, 95%CI: 1.40 – 2.73). 
In contrast, ever-smoking was associated with reduced risk of AAU (IRR: 0.71, 95%CI: 0.55 – 0.92). Other parameters including 
university education, age and axSpA disease duration did not demonstrate significant association with AAU in this cohort using our 
predefined cut-offs, although age and disease duration were assessed per year so may still have a cumulative effect over time.  
Associations with psoriasis 
Psoriasis was reported in 264 (10.9%). In univariable analysis, significant positive associations with psoriasis were seen for older age 
(IRR 1.01, 95%CI: 1.01 – 1.02), BMI (IRR 1.03, 95%CI: 1.01 - 1.05) and ever smoking (IRR of 1.30, 95%CI: 1.00 – 1.70), while the 
participants with axSpA and psoriasis were less likely to be HLA-B27 positive (IRR.0.50, 95%CI: 0.36 – 0.64). Ever-drinking alcohol 
or having a university degree were not significantly different in the psoriasis group compared to the entire cohort. In the multivariable 
analysis (Table 2), only HLA-B27 status remained as independent predictor of psoriasis with an IRR of 0.54 (95%CI: 0.37 – 0.79). 
The other parameters, including age and BMI, did not demonstrate statistically significant association with a diagnosis of psoriasis in 
this axSpA cohort. 
Associations with IBD 
There were 247 (10.2%) patients with a diagnosis of IBD (Table 1). In the univariable analysis, positive associations with IBD were 
older age (IRR 1.02, 95% CI: 1.01 – 1.03) and longer axSpA disease duration (IRR 1.01, 95%CI: 1.00 – 1.02). In contrast, HLA-B27 
was significantly lower in the IBD group (IRR 0.65, 95%CI: 0.43 – 0.89). There were no significant associations in this cohort 
between a diagnosis of IBD and ever-smoking, ever-drinking, BMI or education level.  
Similar to the findings in participants with psoriasis, multivariable analysis identified only HLA-B27 status as an independent negative 
predictor of a diagnosis of IBD with an IRR of 0.63 (95%CI: 0.43 – 0.91). Other parameters including age and axSpA disease 
duration did not demonstrate statistically significant association with IBD (Table 2).  
 
 
Extra-Articular Manifestations and Choice of Biologic 
Nine hundred and forty-seven participants (39.1%) received their first biologic during the course of the observation period. The TNFi 
biologics were adalimumab (n=598, 63.1%; all Humira), etanercept (n=266, 28.1%; consisted of 240 Enbrel and 26 biosimilar 
Benepali), certolizumab (n=73, 7.7%) and golimumab (n=9, 1.0%). One participant (0.1%) treated with the IL-17A inhibitor, 
secukimumab, was excluded from this analysis. Overall, the presence of EAMs did not influence the likelihood of receiving treatment 
with TNFi, with 66% of participants with an EAM receiving TNFi compared with 66.4% without an EAM (p=0.836). 
Treatment and choice of biologic in the BSRBR-AS cohort was at the discretion of the usual treating clinical physician and unrelated 
to participation in the study. In order to determine which demographic factors and disease measurements were associated with 
selection of the soluble fusion protein TNFi, etanercept, compared to the monoclonal antibody TNFis (adalimumab, certolizumab or 
golimumab in this cohort), separate logistic regression models were developed. Univariable analysis revealed that baseline BASDAI 
score (OR= 1.15, 95%CI: 1.06-1.24) and BASFI score (OR= 1.11, 95%CI: 1.04-1.18) were significantly associated with the choice of 
etanercept over monoclonal TNFi. Conversely, having higher education (University and above) was associated with less use of 
etanercept over monoclonal TNFi (OR=0.73, 95%CI: 0.54-0.99). None of other demographic or lifestyle variables, including age, 
gender, disease duration, HLA-B27, smoking and BMI were associated with the choice of TNFi.  
Considering EAMs in the univariable models, ever diagnosis of AAU (as binary yes: no) and number of AAU episodes in the last 12 
months were both significantly associated with less use of etanercept compared to monoclonal TNFi ((OR= 0.29, 95%CI: 0.19 – 
0.46) and  (OR= 0.48, 95%CI: 0.30 – 0.77), respectively)) . Also, patients with ever diagnosis of IBD in any form (all IBD, Crohn’s 
disease alone and ulcerative colitis alone) were less likely to receive etanercept over monoclonal TNFi in univariable models (OR= 
0.35, 95%CI: 0.20 – 0.62). In contrast, ever diagnosis of psoriasis was not associated with choice of any particular TNFi (OR=0.74, 
95%CI: 0.47 – 1.16) (Table 3). 
In multivariable analysis (Table 4), both ever diagnosis of AAU (OR= 0.15, 95%CI: 0.08 - 0.29) and ever diagnosis of IBD (OR= 0.30, 
95%CI: 0.16 - 0.56) remained significantly associated with less use of etanercept compared monoclonal TNFis. Among other factors, 
only BASDAI score had significant association with preference of etanercept over monoclonal TNFi (OR= 1.16, 95%CI: 1.03 - 1.30). 
 
 
DISCUSSION 
In this large real-world cohort of patients with axSpA, EAMs are common, with approximately a third of participants reporting at least 
one EAM. The occurrence of EAMs in this cohort is approximately similar to previous published reports in similar populations (12-14). 
Interestingly, amongst patients who had EAMs, most (84%) of the participants only had a single EAM, suggesting that while there 
may be shared pathogenetic processes between EAMs and axSpA, there are also likely to be unrelated pathogenic mechanisms. 
This is consistent with the existing and emerging pathogenetic and treatment response data for these conditions (15, 16).  
The presence of AAU in this axSpA cohort was significantly associated with HLA-B27 status. This is consistent with previous reports 
(17, 18) and offers a potential strategy for targeted identification of people with AAU in ophthalmology clinics who may have 
underlying axSpA (19-21). Interestingly, participants with IBD and psoriasis had lower rates of HLA-B27 positivity than the overall 
cohort and both had negative associations with HLA-B27 status, consistent with results from a recent study by Varkas et al (22). This 
may indicate that people with psoriasis or IBD and back pain are more likely to be diagnosed with axSpA, regardless of their HLA-
B27 status. Interestingly, a positive HLA-B27 (plus at least 2 other SpA features, which could include psoriasis or IBD) is required to 
fulfil the clinical arm of the ASAS classification criteria for axSpA (10); this may suggest that these participants are more likely to fulfil 
the imaging arm (HLA-B27 not required). An alternative explanation could be that clinicians rely more on diagnostic likelihood and 
clinical acumen rather than rigorously adhering to classification criteria, which would be appropriate as classification criteria are not 
intended for diagnostic use in clinical practice (23, 24). Finally, it is also possible that axSpA is under-diagnosed in patients with 
dominant IBD or psoriasis, particularly those who are HLA-B27 positive (25-28). 
The current study indicated that smoking is associated with lower occurrence of AAU but not associated with psoriasis or IBD. The 
inverse association between AAU and smoking was evident in both unadjusted and adjusted models. However, smoking is 
considered an established risk factor for AAU (29) and its negative association with AAU in this study should be interpreted with 
caution. Firstly, there are differences between studies regarding comparison groups; all participants of the current study had 
confirmed axSpA, in contrast to studies reporting the associations with different background diseases or even in the general 
population (30). Furthermore, while a similar inverse association between smoking and AAU was reported in a recent study using the 
same registry data (31), subsequent analysis showed that smoking does not protect axSpA patients from uveitis attacks (32). Other 
studies have also demonstrated this negative association between smoking and uveitis: Jones et al, in a study of around 1000 
patients from Scotland found that ex-smokers were more than twice as likely to have a history of uveitis compared to current smokers 
(33).  Further investigation using different populations and methodology designed specifically to examine the relationship between 
AAU and smoking in patients with axSpA are required (34). 
The presence of EAMs in general did not increase the likelihood of participants being started on a biologic in this cohort. This 
presumably reflects the focus on axSpA disease activity threshold scores in the axSpA treatment recommendations (2, 4, 5), such 
that the decision to prescribe biologics in axSpA is based largely on axSpA disease activity assessment by the rheumatology team, 
rather than the overall disease burden. IBD and psoriasis often require biologic therapy in their own right (prescribed by 
gastroenterologists or dermatologists) but these patients are unlikely to be captured in this cohort which only recruited participants 
from rheumatology clinics, so the cohort may have missed those with the most severe IBD, psoriasis or AAU. As EAMs contribute to 
the disease burden in axSpA (2, 3), it could be argued that a composite axSpA disease burden score incorporating EAMs, and 
functional measures, might be more representative of the true axSpA disease burden than the current disease activity scores 
(BASDAI and ASDAS), which are dominated by subjective pain and fatigue scores. This approach may be worthy of further study 
and help address the value of combined clinics with other specialties. Although we believe that rheumatologists usually take the full 
burden of disease into consideration, in many countries patient-reported outcomes are used as a reimbursement criterion.  
The presence of EAMs, specifically IBD and AAU, did however influence the choice of TNFi. It is clear that rheumatologists are 
taking the lack of evidence (or even paradox effect) for etanercept in IBD, and to a lesser extent also AAU (35) into consideration 
when choosing a specific TNFi for patients with axSpA. The presence of psoriasis did not appear to influence the choice of TNFi in 
this cohort, which was largely recruited prior to the introduction and wide-spread use of IL-17A inhibitors. EAMs are likely to have a 
major impact on the choice of TNFi versus IL-17A inhibitors in axSpA as there remains concern about the latter exacerbating IBD 
(36,37). In contrast, IL-17A inhibitors have been shown in head-to-head studies to have greater efficacy in psoriasis (38, 39). It 
should be noted that to-date no head-to-head studies of biologics have been reported in axSpA, so data from observational studies 
will be required to help address these questions. It is unfortunate that, due to the funding of the BSRBR-AS, for the majority of the 
data collection period only certain TNFi agents were eligible for inclusion.  For example, the study therefore has no participants 
commencing infliximab as first choice TNFi.  However, in the current analysis all monoclonal antibodies were analysed as a group, 
and we believe it is unlikely that the additional of patients on infliximab (had that data been available) would have altered the 
conclusions in the comparison between monoclonal antibodies versus the soluble fusion protein etanercept.  Beyond the impact of 
EAMs on choice of biologic in axSpA assessed in this study, longitudinal real-world studies will be required to assess the impact of 
EAMs on TNFi retention, which will help inform treatment decisions and recommendations for the use of biologics in axSpA. 
Lindstrom et al reported that AAU and psoriasis but not IBD affect retention of first TNFi in a Swedish cohort of patients with AS (40), 
however more data are needed 
This “real world” cohort provides valuable information on the occurrence of EAMs in axSpA and their influence on TNFi prescribing 
patterns. The main strength of the study is the large sample size and the fact that patients have been recruited from 83 specialist and 
non-specialist centres throughout the UK. To our knowledge this is the first study designed to address this subject. It is reassuring to 
note that clinicians are prescribing in line with licenced and international recommendations. Future analysis will determine whether 
EAMs influence TNF efficacy and survival and whether or not individual TNFi protect patients from incident or flares of existing 
EAMs.  
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Table 1 
 
 
Table 1: Characteristics of entire cohort and subgroups with extra-articular manifestations 
 
  Entire Cohort 
(n=2419) 
 With AAU 
(n=568, 23.5%) 
With psoriasis 
(n=264, 10.9%) 
With IBD 
(n=247, 10.2%) 
Gender (Male)  68.4%  66.7% 67.4% 65.2% 
Age (years), median (IQR)  47.0 (36.0 – 59.0)  51.0 (41.0 – 61.0) 51.5 (38 – 62) 52.0 (40.0 – 63.0) 
AxSpA disease duration (years), median (IQR)  16.0 (7.0 – 30.0)  22.0 (11.0 – 34.0) 17.5 (7.0 – 32.0) 20.0 (8.0 – 35.0) 
BMI (kg/m2), median (IQR)  26.8 (23.9 – 30.7)  27.3 (24.0 – 31.0) 27.7 (24.4 – 31.4) 27.1 (24.0 – 30.8) 
HLA-B27 positive  80.1%  88.7% 66.7% 71.4% 
University degree   27.8%  33.5% 27.2% 24.8% 
Ever smoker  56.2%  50.1% 62.7% 59.7% 
Ever alcohol consumption  93.0%  94.2% 94.0% 92.1% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 
 
 
Table 2: Factors and covariates associated with a diagnosis of specific EAM in axSpA patients, multivariable models 
 
Parameter B Std. Error p value 
Incidence Rate Ratio 
(IRR) 95% CI for IRR 
A. Diagnosis of AUU      
(Intercept) -2.370 0.2788 <0.001 0.093 0.054 - 0.161 
HLA-B27 positive (vs negative) 0.669 0.1710 <0.001 1.953 1.396 - 2.730 
University degree (vs lower) 0.165 0.1507 0.273 1.179 0.878 - 1.585 
Ever smoking (vs never) -0.349 0.1322 0.008 0.706 0.545 - 0.915 
Age (years) 0.009 0.0053 0.093 1.009 0.999 - 1.019 
AxSpA disease duration (years) 0.005 0.0050 0.305 1.005 0.995 - 1.015 
B. Diagnosis of Psoriasis      
(Intercept) -3.069 0.592 0.000 0.046 0.015 - 0.148 
HLA-B27 positive (vs negative) -0.621 0.197 0.002 0.538 0.365 - 0.791 
University degree (vs lower) 0.326 0.283 0.248 1.386 0.796 - 2.412 
Ever smoking (vs never) 0.256 0.228 0.262 1.292 0.826 - 2.020 
Age (year) 0.009 0.007 0.173 1.009 0.996 - 1.022 
BMI (kg/m2) 0.022 0.016 0.155 1.023 0.992 - 1.055 
C. Diagnosis of IBD      
(Intercept) -2.698 0.3617 <0.001 0.067 0.033 - 0.137 
HLA-B27 positive (vs negative) -0.466 0.1894 0.014 0.627 0.433 - 0.909 
Age (year) 0.012 0.0079 0.128 1.012 0.997 - 1.028 
AxSpA disease duration (years) 0.003 0.0078 0.671 1.003 0.988 - 1.019 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 
 
 
Table 3: Summary of factors associated with choice of etanercept over monoclonal antibody TNFis in axSpA patients  
(summary of separate univariable models) 
 
Variable Wald p Value OR 95% CI for OR 
Gender (Male vs Female) 3.561 0.059 1.351 0.988 – 1.847 
Age (years) 0.842 0.359 0.995 0.984 – 1.006 
Disease duration (years) 2.062 0.151 0.992 0.980 – 1.003 
BASDAI Score 12.226 <0.001 1.146 1.062 – 1.237 
BASFI Score 10.393 0.001 1.107 1.041 – 1.178 
HLA-B27 Positivity 0.033 0.856 1.038 0.692 – 1.557 
Smoking (Current vs none) 1.525 0.217 1.268 0.870 – 1.848 
Smoking (Ex-smoking vs none) 0.084 0.772 1.054 0.736 – 1.510 
Education (Ordinal) 3.543 0.060 0.893 0.793 – 1.005 
Education (University Degree vs lower) 4.084 0.043 0.730 0.539 – 0.991 
BMI (Kg/m2) 0.365 0.546 0.956 0.826 – 1.106 
AAU (any) 27.943 <0.001 0.294 0.187 – 0.463 
AAU episodes in last 12 Months 9.336 0.002 0.484 0.304 – 0.771) 
IBD (Crohn’s disease or ulcerative colitis) 13.081 <0.001 0.354 0.201 – 0.621 
Crohn’s disease 9.457 0.002 0.044 0.006 – 0.323 
Ulcerative colitis 7.456 0.006 0.192 0.056 – 0.628 
Psoriasis 1.707 0.191 0.738 0.468 – 1.164 
 
  
 
 
 
 
 
 
 
 
 
Table 4 
 
 
Table 4: Summary of factors associated with choice of etanercept over monoclonal TNFis in axSpA patients 
(summary of multivariable model) 
 
Variable Wald p Value OR 95% CI for OR 
BASDAI Score 5.941 0.015 1.158 1.029 – 1.304 
BASFI Score 0.315 0.577 1.028 0.932 – 1.135 
Education (University Degree vs lower) 1.098 0.295 0.836 0.597 – 1.169 
AAU (any) 35.266 <0.001 0.154 0.083 – 0.286 
IBD (Crohn’s disease or ulcerative colitis) 13.853 <0.001 0.296 0.156 – 0.562 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
